about
miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid CancerRight pulmonary artery atresia with left circumflex coronary collaterals supplying the affected lung diagnosed by V/Q scintigraphy and CTA: a case report and review of the literature.MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: a systematic review and meta-analysis.Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases.Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors.Value of post-therapeutic ¹³¹I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma.Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.Afamin promotes glucose metabolism in papillary thyroid carcinoma.Dual-phase (99m)Tc-MIBI scintigraphy with delayed neck and thorax SPECT/CT and bone scintigraphy in patients with primary hyperparathyroidism: correlation with clinical or pathological variables.More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysisClinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapySorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis
P50
Q37035505-EBB67744-6DC3-4A84-A584-900EEDB8DF14Q37738239-0E1940CC-1274-4E62-BC33-B0CC3320D65BQ38237894-6F51B9E4-3CB5-41AF-9DF6-B8A8E51DD99BQ38288967-208EB140-856D-475B-9E4C-F8ACA8F3E40CQ38757091-1664ACC9-79C4-44E7-8C80-9DB9EE2DC1DAQ40415771-6EDD87F3-5572-4C07-A29F-E0EE44010953Q40805907-E0D550BA-CE81-4E60-B9EE-CA0FDC9120FFQ50901388-BAC73AE5-4ECC-426C-A751-15037F2A16F6Q51008295-4ED610A9-4B93-4AFA-AE7B-48670451D588Q51284154-739B8EA4-0221-4840-947D-DE8AA4DBA3DDQ51689854-7CD371F1-DC66-45B5-8CAB-8C1C6110CD27Q53056442-8F914A74-3743-4BCD-BA63-EA48645B6C94Q54367722-EF8C499D-84E3-4219-BA15-A30B9C236DA7Q85699726-AE6B7486-20BE-4B7E-BA00-7AC09471DDA2Q85833040-8692322C-3ABF-4AB8-A33B-1C24E2255BB9Q86887158-C969F089-E5D8-46C3-9D9A-B6DFAB897840
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Chen-Tian Shen
@en
Chen-Tian Shen
@nl
type
label
Chen-Tian Shen
@en
Chen-Tian Shen
@nl
prefLabel
Chen-Tian Shen
@en
Chen-Tian Shen
@nl
P31
P496
0000-0001-5943-4418